There was more bad news for drug firms from Germany Dec. 1, when a new law redefining the relationship between the pharmaceutical industry and the reimbursement authority (G-BA) failed to secure drug firms the degree of influence they have long been seeking. Furthermore, it appeared to endorse, rather than redress, the existing lack of transparency in the G-BA process, according to industry, by granting immunity from external challenges to the auhtority’s decision-makers.
The set-back comes as the G-BA takes on an increasingly influential role in Europe’s largest market. It’s at the center of a new, stringent cost-benefit assessment process (known as AMNOG) that threatens reference pricing for drugs that fail to show compelling additional benefit over existing treatments
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?